Ozempic, insulin, and diabetes: sorting fact from TikTok

What did @aliciax1702 actually say?

Honestly, the transcript here is nearly unusable. The auto-generated captions captured fragments like "it's a few more would be you you School It wasn't really good at all" — which tells us nothing coherent about the actual content. The caption, however, states this is a "divulgación científica" (science communication) video about diabetes, insulin, and how Ozempic works, with a clear disclaimer that it is not promotional and that viewers should consult a doctor before taking anything. That disclaimer is worth crediting upfront.

Because the transcript does not yield verifiable spoken claims, this fact-check focuses on what is commonly communicated in Spanish-language Ozempic explainer videos of this type, and whether the framing in the caption itself holds up scientifically.

Does the science back this up?

The basic framing, that Ozempic (semaglutide) works differently from insulin and carries real side effects, is accurate. The science on GLP-1 receptor agonists is unusually solid for a weight-management drug class.

Semaglutide mimics glucagon-like peptide-1, a hormone secreted in the gut after eating. It slows gastric emptying, suppresses appetite via hypothalamic pathways, and stimulates glucose-dependent insulin release. The SUSTAIN and STEP trial programs (Wilding et al., 2021, New England Journal of Medicine) showed sustained weight loss of roughly 15 percent of body weight over 68 weeks in non-diabetic adults with obesity. In people with type 2 diabetes, the drug also reduces HbA1c meaningfully. These are not trivial effects. The side effect profile, primarily nausea, vomiting, and gastrointestinal distress, is also well-documented and the caption's warning about side effects is appropriate.

What did they get wrong (or right)?

Without a reliable transcript, it is impossible to fact-check specific spoken claims. That is a real limitation, and readers should know it. What we can say is that the caption's framing is responsible: the creator explicitly warns against self-medicating, names side effects as a real concern, and urges medical consultation. That is more than most viral Ozempic content does.

Common errors in this video category include overstating the mechanism as simply "blocking hunger," conflating Ozempic (approved for type 2 diabetes) with Wegovy (approved for weight management, same molecule, different dose and indication), and ignoring contraindications like personal or family history of medullary thyroid carcinoma. If this video repeated those errors, they matter. If it did not, credit is due. We simply cannot confirm either way from the available transcript.

What should you actually know?

Here is what is settled in the literature. Semaglutide works primarily through GLP-1 receptor agonism in the brain and gut, not by mimicking insulin. It does not replace insulin in people who need it. Davies et al. (2021, Diabetes Care) confirmed cardiovascular benefit in high-risk type 2 diabetes patients, but cardiovascular outcomes data for purely weight-management use in otherwise healthy individuals is still accumulating.

Side effects are not rare. In the STEP 1 trial, over 40 percent of participants reported nausea and roughly 25 percent reported vomiting at some point during treatment. Rare but serious risks include pancreatitis and, based on rodent data, a theoretical thyroid C-cell concern, which is why it carries a black-box warning. A doctor's involvement is not optional advice; it is a clinical necessity. The caption got that right.

• Semaglutide is not a weight-loss "shortcut." Discontinuation typically leads to weight regain (Rubino et al., 2021, NEJM).
• Compounded semaglutide is not the same as Ozempic or Wegovy. Formulation, purity, and dosing differ in ways that matter clinically.
• GLP-1 agonists do not cure type 2 diabetes. They manage blood glucose and body weight while the drug is active.